GlassScriptPhysician profile
Noe B Mateo
NPI 1255307203
$6,407.51
in general payments reported to CMS, 2019-2025
45 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $396 · 2021: $524 · 2022: $934 · 2023: $1,697 · 2024: $777 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.46 | 2019-2025 | |
| Gilead Sciences, INC. | $778.80 | 2019-2024 | Epclusa |
| Melinta Therapeutics, LLC | $735.68 | 2019-2024 | Rezzayo, Orbactiv, Kimyrsa |
| Astrazeneca Pharmaceuticals LP | $397.53 | 2019-2024 | Airsupra, Breztri, Tezspire |
| Allergan, INC. | $326.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $262.02 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Viiv Healthcare Company | $239.28 | 2019-2020 | |
| Harmony Biosciences LLC | $200.69 | 2022-2025 | Wakix |
| Grifols USA, LLC | $173.53 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $161.33 | 2019-2024 | Eohilia, Entyvio |
| Amgen INC. | $156.38 | 2019-2023 | Tezspire |
| Genzyme Corporation | $139.95 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.60 | 2019-2022 | |
| Insmed, INC. | $115.89 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $111.95 | 2022-2023 | Rebyota |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noe Mateo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.